DEVELOPMENT OF A RIA FOR HUMAN ERYTHROPOIETIN

促红细胞生成素（Epo）是一种由肾脏和/或肝脏产生的激素 它决定了产生的红细胞的数量。 近日 编码该糖蛋白激素的cDNA的核苷酸序列具有 确定了 从这个和胰蛋白酶的氨基酸序列 肽的完整氨基酸序列的蛋白质已经推导出来。 该项目的目标是合成各种肽类似物， Epo氨基酸序列的区域，并使用这些肽类似物作为 用于产生抗血清的抗原，所述抗血清可用于开发RIA 为了Epo 通过这种方法开发的免疫测定不需要纯的 促红细胞生成素，但只需要生产纯肽 类似物，可以非常经济地大规模合成。 的 RIA将在本项目期间开发， 提供给医生，临床实验室和研究人员， 红细胞生成障碍患者的诊断和监测 治疗患有各种肾脏疾病的患者。

Erythropoietin (Epo) is a hormone produced by the kidneys and/or liver which determines the number of red blood cells produced. Recently, the nucleotide sequence of a cDNA which encodes this glycoprotein hormone has been determined. From this and from the amino acid sequence of tryptic peptides the complete amino acid sequence of the protein has been deduced. The goal of this project is to synthesize peptide analogs of various regions of the Epo amino acid sequence, and to use these peptide analogs as antigens for the production of antisera which can be used to develop a RIA for Epo. An immunoassay developed by this procedure would not require pure erythropoietin, but would only require the production of a pure peptide analog, which can by synthesized very economically on a large scale. The RIA which is to be developed during this project will be commercially available to physicians, clinical laboratories, and researchers for the diagnosis of patients with erythropoietic disorders and for monitoring the treatment of patients with various kidney disorders.